Visitors can check out the Forum FAQ by clicking this link. You have to register before you can post: click the REGISTER link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. View our Forum Privacy Policy.
Want to receive the latest contracting news and advice straight to your inbox? Sign up to the ContractorUK newsletter here. Every sign up will also be entered into a draw to WIN £100 Amazon vouchers!
You are not logged in or you do not have permission to access this page. This could be due to one of several reasons:
You are not logged in. If you are already registered, fill in the form below to log in, or follow the "Sign Up" link to register a new account.
You may not have sufficient privileges to access this page. Are you trying to edit someone else's post, access administrative features or some other privileged system?
If you are trying to post, the administrator may have disabled your account, or it may be awaiting activation.
India is a major producer of generics (off-patent) drugs, mainly through a company called Ranbaxy. It's not surprising that the odd batch might be dodgy, if its systemic then you'd need to worry.
A statement from the MHRA said it was not recalling the medicines people had at home because, although they had not been manufactured to Good Manufacturing Practice standards, there was no evidence of a patient safety risk from medicines that have been sold in the UK.
However, it said it had to act in the public interest - and poor manufacturing standards could not be allowed to continue.
Import tests
An inspection at the Waluj factory in March found some risk of cross-contamination because of poor cleaning practices, and defects in building fabric and the ventilation systems at the site.
There was also evidence of forged documents relating to staff training records that had been re-written.
so its not like they are breaking new ground, forging qualifications and not following basic procedures..
Leave a comment: